The pharmaceutical company co-led a series C round for AAV gene therapy developer Freeline that took its total funding to $275m.
UK-based gene therapy developer Freeline closed a $120m series C round today that was co-led by pharmaceutical firm Novo, investment adviser Eventide Asset Management and investment management firm Wellington Management.
The round included commercialisation firm Syncona, which supplied $40m in a December 2019 first tranche, as well as Cowen Healthcare Investments, Acorn Bioventures and Ample Plus Fund.
Founded in 2015 by Syncona, Freeline is working on adeno-associated virus (AAV)-based gene therapies aimed at the liver to tackle chronic, systemic conditions…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
